查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1450314

心肌肌钙蛋白市场：现况分析与预测（2023-2030）

Cardiac Troponin Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 154 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计 2023 年至 2030 年，心肌肌钙蛋白市场的复合年增长率约为 10.2%。心肌肌钙蛋白是心肌受损时释放到血液中的一种蛋白质，使其成为诊断心臟病和其他心臟病的重要标记。心臟病、心臟衰竭和心肌梗塞等心血管疾病的流行是心肌肌钙蛋白市场的关键驱动因素。由于这些疾病持续影响全世界很大一部分人口，因此对用于诊断和监测这些疾病的肌钙蛋白检测的需求仍然很高。例如，到 2024 年，全球将有约 6.2 亿人患有心臟病和循环系统疾病。据估计，全世界每 13 个人中就有 1 人患有心臟或循环系统疾病。此外，技术进步促使了更灵敏、更特异的肌钙蛋白测量方法的发展。这些进步提高了肌钙蛋白检测的准确性和可靠性，支持其在临床实践中的采用。此外，随着人口老化，人们更容易患心血管疾病，从而增加了对包括肌钙蛋白在内的心臟生物标记测试的需求。

根据环境，市场分为实验室测试、现场护理（POC）测试。预计实验室检测治疗类别在预测期内将表现出最高的复合年增长率。基于实验室的肌钙蛋白测量通常具有高精度和准确度，使其适合心血管疾病的诊断和监测。医疗保健提供者通常依靠实验室测试来获得准确的肌钙蛋白测量结果，特别是在需要进行系列测试或评估患有复杂医疗状况的患者时。例如，2021 年推出了 ARCHITECT hsTnI I 20 检测方法。这种高度灵敏的肌钙蛋白 I 测量方法具有更高的准确性和灵敏度，可准确诊断和排除心臟病。此外，基于实验室的测试平台还提供全面的心臟生物标记测试功能，包括肌钙蛋白测定以及其他相关测试，例如血脂谱、电解质板和心臟成像。

根据适应症，心肌肌钙蛋白市场分为心肌梗塞、急性冠状动脉症候群、冠状动脉心臟病、充血性心臟衰竭等。其中，心肌梗塞领域的市占率预计较高。儘管预防性心臟病学和心血管治疗取得了进展，但心肌梗塞仍然是全世界发病和死亡的主要原因。人口老化、高血压、糖尿病和肥胖等心血管危险因子的盛行率上升以及生活方式的改变导致心臟病发病率增加，使得肌钙蛋白在急性心肌梗塞的诊断和治疗中发挥重要作用，从而推动了检测需求。

根据最终用户，心肌肌钙蛋白市场分为医院、诊断中心等。其中，在预测期内，医院将更多地采用心肌肌钙蛋白。本院是治疗心肌梗塞、心臟衰竭等急性心血管疾病患者的主要场所。这些疾病的盛行率不断上升，加上人口老化和心血管危险因子的盛行率不断增加，导致住院患者数量增加，这些地区对肌钙蛋白检测的需求也增加。此外，医院还实施了急性心血管疾病评估和管理的标准化临床路径和方案，并将肌钙蛋白检测纳入常规临床实践。遵守实证指引可确保肌钙蛋白测试的一致和最佳使用，并支持及时诊断、风险分层和治疗启动。

为了更瞭解心肌肌钙蛋白产业的市场实施情况，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚太地区（中国、日本、印度、亚太其他地区）和世界其他地区。由于心血管疾病的盛行率不断上升、医疗专业人员和公众对心肌肌钙蛋白的认识不断提高、先进技术的市场发展以及治疗选择的增加，北美心肌肌钙蛋白市场将持续成长。例如，根据 CDC 的数据，2019 年，美国每年约有 805,000 人心臟病发作。大约五分之一的心臟病发作者没有任何症状，这意味着伤害已经造成，但患者并没有意识到。

市场主要参与者包括F. Hoffmann-La Roche Ltd.、BIOMERIEUX.、Abbott、Siemens Healthcare Private Limited、Beckman Coulter, Inc、Trinity Biotech、Bio-Techne、PerkinElmer Inc、Bio-Rad Laboratories, Inc、Eurolyser Diagnostica GmbH等

目录

第一章 市场介绍

  • 市场定义
  • 主要目标
  • 利益相关者
  • 限制

第二章 研究方法或前提条件

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对心肌肌钙蛋白市场的影响

第六章2020-2030年全球心肌肌钙蛋白市场收入

第七章市场洞察：依环境分类

  • 临床检查
  • 护理点 (POC) 测试

第八章市场洞察：依迹象分类

  • 心肌梗塞
  • 急性冠状动脉综合症
  • 冠状动脉心臟疾病
  • 充血性心力衰竭
  • 其他

第 9 章 市场洞察：依最终用户分类

  • 医院
  • 诊断中心
  • 其他

第10章市场洞察：依地区

  • 北美心肌肌钙蛋白市场
    • 美国
    • 加拿大
    • 其他北美
  • 欧洲心肌肌钙蛋白市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太心肌肌钙蛋白市场
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 其他地区心肌肌钙蛋白市场

第十一章心肌肌钙蛋白市场动态

  • 市场驱动力
  • 市场课题
  • 影响分析

第十二章心肌肌钙蛋白市场机会

第十三章心肌肌钙蛋白市场趋势与见解

第十四章需求面和供给面分析

  • 需求面分析
  • 供给侧分析

第十五章价值链分析

第十六章价格分析

第17章 竞争场景

  • 竞争格局
    • 波特五力分析

第十八章 公司简介

  • F. Hoffmann-La Roche Ltd.
  • BIOMERIEUX.
  • Abbott
  • Siemens Healthcare Private Limited
  • Beckman Coulter, Inc
  • Trinity Biotech
  • Bio-Techne
  • PerkinElmer Inc
  • Bio-Rad Laboratories, Inc
  • Eurolyser Diagnostica GmbH

第19章 免责声明

简介目录
Product Code: UMHE212648

The Cardiac troponin market is expected to register a CAGR of approx. 10.2% over the period of 2023-2030. Cardiac troponins are proteins released into the bloodstream when the heart muscle is damaged, making them essential markers for diagnosing heart attacks and other cardiac conditions. The prevalence of cardiovascular diseases, such as heart attacks, heart failure, and myocardial infarctions, is a significant driver of the cardiac troponin market. As these conditions continue to affect a large portion of the population globally, the demand for troponin testing to diagnose and monitor these diseases remains high. For instance, in 2024, There are around 620 million people living with heart and circulatory diseases across the world. Globally it's estimated that 1 in 13 people are living with a heart or circulatory disease. Furthermore, advances in technology have led to the development of more sensitive and specific troponin assays. These advancements improve the accuracy and reliability of troponin testing, driving adoption in clinical practice. Additionally, the aging population is more susceptible to cardiovascular diseases, leading to a higher demand for cardiac biomarker testing, including troponin..

Based on setting, the market is segmented into Laboratory Testing, Point-of-Care (POC) Testing. The laboratory testing therapy category is expected to witness the highest CAGR during the forecast period. Laboratory-based troponin assays typically offer high accuracy and precision, making them well-suited for the diagnosis and monitoring of cardiovascular diseases. Healthcare providers often rely on laboratory testing to obtain precise troponin measurements, especially in cases requiring serial testing or when assessing patients with complex medical conditions. For instance, In 2021, ARCHITECT hsTnI I 20 assay. This high-sensitivity troponin I assay boasts improved precision and sensitivity for accurate heart attack diagnosis and exclusion. Additionally, Laboratory-based testing platforms offer comprehensive capabilities for cardiac biomarker testing, including troponin assays, alongside other relevant tests such as lipid profiles, electrolyte panels, and cardiac imaging..

Based on indication, the cardiac troponin market has been classified as myocardial infarction, acute coronary syndrome, coronary heart disease, congestive heart failure, and others. Among them, the myocardial infarction segment is expected to grow at a higher share in the market. Despite advancements in preventive cardiology and cardiovascular care, heart attacks remain a leading cause of morbidity and mortality globally. The aging population, rising prevalence of cardiovascular risk factors, such as hypertension, diabetes, and obesity, and lifestyle changes contribute to the increasing incidence of heart attacks, driving demand for troponin testing in the diagnosis and management of acute myocardial infarction.

Based on the end-user, the cardiac troponin market has been classified into hospitals, diagnostic centers, others. Among them, the hospitals category is to witness higher adoption of Cardiac Troponin during the forecast period. : Hospitals are the primary settings for managing patients with acute cardiovascular conditions, such as myocardial infarction and heart failure. The rising incidence of these conditions, coupled with population aging and the increasing prevalence of cardiovascular risk factors, leads to higher patient admissions to hospitals, driving demand for troponin testing in these settings. Moreover, Hospitals implement standardized clinical pathways and protocols for the evaluation and management of acute cardiovascular conditions, incorporating troponin testing into routine practice. Adherence to evidence-based guidelines ensures consistent and optimal use of troponin testing, supporting timely diagnosis, risk stratification, and treatment initiation.

For a better understanding of the market adoption of the Cardiac troponin industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America cardiac troponin market is expected to continue to grow in the coming years, driven by the increasing prevalence of cardiovascular disease and growing awareness of cardiac troponin among healthcare professionals and the general population, development of advanced techniques and the rise in treatment option. For instance, in 2019, according to CDC, Every year, about 805,000 people in the United States have a heart attack. About 1 in 5 heart attacks are silent, the damage is done, but the person is not aware of it.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd., BIOMERIEUX., Abbott, Siemens Healthcare Private Limited, Beckman Coulter, Inc, Trinity Biotech, Bio-Techne, PerkinElmer Inc, Bio-Rad Laboratories, Inc, Eurolyser Diagnostica GmbH.

TABLE OF CONTENTS

1. MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Cardiac Troponin Market
  • 2.2.Research Methodology of the Cardiac Troponin Market
  • 2.4.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE CARDIAC TROPONIN MARKET

6. GLOBAL CARDIAC TROPONIN MARKET REVENUE, 2020-2030F

7. MARKET INSIGHTS BY SETTING

  • 7.1.Laboratory Testing
  • 7.2.Point-of-Care (POC) Testing

8. MARKET INSIGHTS BY INDICATION

  • 8.1.Myocardial Infarction
  • 8.2.Acute Coronary Syndrome
  • 8.3.Coronary heart disease
  • 8.4.Congestive Heart Failure
  • 8.5.Others

9. MARKET INSIGHTS BY END-USERS

  • 9.1.Hospitals
  • 9.2.Diagnostic Centers
  • 9.3.Others

10. MARKET INSIGHTS BY REGION

  • 10.1NORTH AMERICA CARDIAC TROPONIN MARKET
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2EUROPE CARDIAC TROPONIN MARKET
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3ASIA PACIFIC CARDIAC TROPONIN MARKET
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4REST OF THE WORLD CARDIAC TROPONIN MARKET

11. CARDIAC TROPONIN MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12. CARDIAC TROPONIN MARKET OPPORTUNITIES

13. CARDIAC TROPONIN MARKET TRENDS & INSIGHTS

14. DEMAND AND SUPPLY SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15. VALUE CHAIN ANALYSIS

16. PRICING ANALYSIS

17. COMPETITIVE SCENARIO

  • 17.1.Competitive Landscape
    • 17.1.1Porter's Five forces analysis

18. COMPANY PROFILED

  • 18.1.F. Hoffmann-La Roche Ltd.
  • 18.2.BIOMERIEUX.
  • 18.3.Abbott
  • 18.4.Siemens Healthcare Private Limited
  • 18.5.Beckman Coulter, Inc
  • 18.6.Trinity Biotech
  • 18.7.Bio-Techne
  • 18.8.PerkinElmer Inc
  • 18.9.Bio-Rad Laboratories, Inc
  • 18.10.Eurolyser Diagnostica GmbH

19. DISCLAIMER